Dcf Advisers, LLC Aerie Pharmaceuticals Inc Transaction History

Dcf Advisers, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $60,515 - $144,685	-9,500 Reduced 5.68%	157,665 $2.39 Million
Q2 2022 Aug 11, 2022	SELL	$4.95 - $9.16 $110,880 - $205,184	-22,400 Reduced 11.82%	167,165 $1.25 Million
Q1 2022 May 13, 2022	SELL	$5.64 - $9.8 $14,100 - $24,500	-2,500 Reduced 1.3%	189,565 $1.73 Million
Q4 2021 Feb 10, 2022	BUY	$7.02 - $13.33 $390,059 - $740,668	55,564 Added 40.71%	192,065 $1.35 Million
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $511,675 - $751,692	45,201 Added 49.51%	136,501 $1.56 Million
Q2 2021 Aug 13, 2021	SELL	$15.16 - $18.97 $18,192 - $22,764	-1,200 Reduced 1.3%	91,300 $1.46 Million
Q1 2021 May 12, 2021	BUY	$13.12 - $20.9 $754,400 - $1.2 Million	57,500 Added 164.29%	92,500 $1.65 Million
Q4 2020 Feb 12, 2021	BUY	$9.12 - $14.49 $319,200 - $507,150	35,000 New	35,000 $473,000
Q1 2020 May 12, 2020	SELL	$11.84 - $25.52 $242,720 - $523,160	-20,500 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$17.72 - $25.1 $363,260 - $514,550	20,500 New	20,500 $495,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.